| P50 | author | Rob Striker | Q54075098 |
| P2093 | author name string | John P Rice | |
| | Mary J Lindstrom | |
| | Michael R Lucey | |
| | David Burnett | |
| | Daniel D Cornett | |
| | Helena Tsotsis | |
| | Jill Sawyer | |
| | Patricia Voermans | |
| P2860 | cites work | Outcomes of treatment for hepatitis C virus infection by primary care providers | Q24601722 |
| | Prevention and control of infections with hepatitis viruses in correctional settings | Q26151271 |
| | A new look at the statistical model identification | Q26778401 |
| | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 |
| | Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 |
| | Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus | Q28279955 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | Diagnosis, management, and treatment of hepatitis C | Q29620656 |
| | Natural history of chronic hepatitis C | Q29620673 |
| | Chronic liver disease mortality among male prison inmates in Texas, 1989-2003. | Q33799309 |
| | Pathogenesis, natural history, treatment, and prevention of hepatitis C. | Q33841882 |
| | Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C | Q34113801 |
| | Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 |
| | Psychiatric disorders and repeat incarcerations: the revolving prison door. | Q34891905 |
| | A framework for management of hepatitis C in prisons | Q36479796 |
| | Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations | Q36843554 |
| | Treating hepatitis C in the prison population is cost-saving | Q37299503 |
| | High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. | Q37769280 |
| | Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients | Q39913723 |
| | Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response? | Q42984882 |
| | Induction Pegylated Interferon Alfa-2a and High Dose Ribavirin Do Not Increase SVR in Heavy Patients With HCV Genotype 1 and High Viral Loads | Q42999649 |
| | Meta-analysis: insulin resistance and sustained virological response in hepatitis C. | Q43037279 |
| | Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 |
| | Treatment of chronic hepatitis C in a state correctional facility | Q43042164 |
| | Access to treatment of hepatitis C in prison inmates | Q43657166 |
| | Gaps in the achievement of effectiveness of HCV treatment in national VA practice | Q43879719 |
| | Comparison of CAGE questionnaire and computer-assisted laboratory profiles in screening for covert alcoholism | Q68094019 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| | Hepatitis C virus | Q708693 |
| P304 | page(s) | 1252-1260 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Comparison of hepatitis C virus treatment between incarcerated and community patients | |
| P478 | volume | 56 | |